Rainbow Children’s Medicare Limited has reported strong financial performance for the quarter and financial year ended March 31, 2026. The company has announced a final dividend of ₹3.50 per share. Additionally, the Board has approved the re-appointment of key leadership figures, including Dr. Ramesh Kancharla and Dr. Dinesh Kumar Chirla, for another five-year term, ensuring continuity in the company’s strategic vision and medical leadership.
Financial Performance Overview
For the financial year ended March 31, 2026, Rainbow Children’s Medicare reported robust growth. The company achieved a standalone profit after tax of ₹2,500.16 million, up from ₹2,375.83 million in the previous year. On a consolidated basis, the profit after tax reached ₹2,815.44 million, compared to ₹2,442.27 million in the prior year, reflecting the company’s sustained expansion and operational efficiency.
Dividend Recommendation
The Board of Directors has recommended a final dividend of ₹3.50 per equity share, representing a 35% return on the face value of ₹10 per share for the financial year ended March 31, 2026. This dividend payout is subject to approval by shareholders during the upcoming 28th Annual General Meeting, scheduled for July 29, 2026.
Strategic Leadership Reappointments
To maintain stable leadership, the Board has approved several key re-appointments for a new five-year term effective August 11, 2026, through August 10, 2031. Dr. Ramesh Kancharla continues his tenure as Chairman and Managing Director, while Dr. Dinesh Kumar Chirla remains as a Whole Time Director. Additionally, the company has extended the terms of Independent Directors Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati, reinforcing the company’s commitment to strong corporate governance.
Operational Expansion
During the fiscal year, the company successfully integrated new entities into its portfolio, including Prashanthi Medicare Private Limited and Pratiksha Women & Child Care Hospital Private Limited. These acquisitions have contributed significantly to the consolidated revenue, adding ₹191.52 million and ₹648.70 million respectively from the dates of their consolidation, underscoring the company’s aggressive and successful growth strategy in the healthcare sector.
Source: BSE
